Why Is INCYTE CORP (INCY) Stock Up Today?

INCY stock is up 6.81% to $126.97 in a session marked by strong earnings performance and an upward revision of full-year sales guidance. The biopharmaceutical company reported second-quarter 2026 net product sales of $1.49 billion, a 40% increase year-over-year, driven by demand growth across its marketed portfolio. The stock opened at $119.06 and climbed to a session high of $127.05 at 11:00 AM ET.

What Happened

Incyte reported second-quarter 2026 non-GAAP earnings per share of $3.09, exceeding estimates by $0.94, and revenue of $1.67 billion, surpassing expectations by $180 million. The company raised its full-year 2026 sales guidance to a range of $5.13 billion to $5.26 billion, up from $4.77 billion to $4.94 billion. This revision followed a settlement with the Centers for Medicare & Medicaid Services, which contributed to the improved outlook. Strong performance from key products such as Jakafi, Opzelura, and the oncology portfolio supported the results. The company also issued a Form 8-K disclosing its financial results and business updates.

What The Data Shows

The stock opened near the lower end of its 52-week range and climbed to a new 52-week high of $127.05. The intraday session saw a high of $127.05 and a low of $118.00. Trading volume of 0.9 million shares is 0.5 times the 3-month average. The stock has risen 2.1% over the past 8 sessions, from $116.40 to $118.87. Recent insider transactions include six sales totaling $5.4 million over the last 90 days, with no insider purchases recorded.

What To Watch

The company’s revised full-year guidance and strong product performance will be key to monitor. No earnings date is provided, but coverage breadth remains active with 11 stories from 7 sources in the last 36 hours.